Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE: Nursing Roles in Managing Patients With Gastroenteropancreatic Neuroendocrine Tumors

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a diverse family of cancers that occur within the gastrointestinal tract and pancreas. Peptide receptor radionuclide therapy (PRRT) via ¹⁷⁷Lu-DOTATATE is a newer therapeutic option for certain patients with somatostatin receptor–positive GEP-NETs.

Objectives: This review informs on how oncology nurses treating patients with GEP-NETs receiving PRRT using ¹⁷⁷Lu-DOTATATE can facilitate care.

Methods: Guidance on the monitoring, management, and care of patients undergoing PRRT for GEP-NETs was developed based on published literature and the nursing experience of the authors. A case study is summarized to highlight key concepts.

Findings: Oncology nurses provide assessment, education, direct care, and emotional support when caring for patients with GEP-NETs receiving PRRT with ¹⁷⁷Lu-DOTATATE. As the treatment landscape evolves, so too will these roles and responsibilities.